$XBI $70.26 | -4.03%
Table of Contents:
Covid Updates
Pipeline Updates
#OLMA +8.5% Olema Oncology Provides Clinical Update Reflecting Strong Progress Across OP-1250 Development Program
#CLBS +4.2% Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group
#SEEL +3.7% Seelos Therapeutics Announces Statistically Significant Data in a Gene Therapy Study of SLS-004 in Dementia with Lewy Bodies
#BLUE +3.3% FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy
#FUSN +0.6% Fusion Pharmaceuticals Provides Updates on FPI-1434 and FPI-1966 Clinical Programs
#ELDN -2.3% Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation
#IMPL -3.1% Impel Pharmaceuticals to Present Trudhesa® Data at the 64th Annual Meeting of the American Headache Society
#BBIO -4.1% bridgebio pharma to present phase 2b data and pivotal phase 3 study design of encaleret in autosomal dominant hypocalcemia type 1 (adh1) at the endocrine society (endo) 2022 annual conference
#SRRK -5.9% Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference
#VRNA -14% Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
#APVO -14.4% Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
#DBVT +79.6% DBV Technologies Announces Private Placement Financing of $194 Million
#BCRX -3.6% BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin America
Posted by JM